Workflow
Arcus Biosciences(RCUS)
icon
搜索文档
Arcus Biosciences(RCUS) - 2023 Q4 - Annual Results
2024-02-22 05:08
Exhibit 99.1 Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update HAYWARD, Calif. – (BUSINESS WIRE) – February 21, 2024 – Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a pipeline update on its clinical- stage ...
Arcus Biosciences(RCUS) - 2023 Q3 - Earnings Call Transcript
2023-11-08 13:54
Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Pia Eaves - Head of Investor Relations And Strategy Terry Rosen - Co-Founder, Chairman & CEO Dimitry Nuyten - Chief Medical Officer Jennifer Jarrett - COO & Director Robert Goeltz - Principal Financial & Accounting Officer & CFO Juan Jaen - President and Head of Research Yigal Nochomovitz - Citigroup Jonathan Miller - Evercore ISI Peter Lawson - Barclays Bank Robin Karnauskas - Truist Kaveri Pohlman - BTIG Mara ...
Arcus Biosciences(RCUS) - 2023 Q3 - Quarterly Report
2023-11-08 05:11
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 ______________ ...
Arcus Biosciences(RCUS) - 2023 Q2 - Quarterly Report
2023-08-07 20:13
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 Arcus Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-3898 ...
Arcus Biosciences(RCUS) - 2023 Q1 - Quarterly Report
2023-05-10 04:15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 Arcus Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-389 ...
Arcus Biosciences(RCUS) - 2022 Q4 - Annual Report
2023-03-01 05:18
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O R 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38419 Arcus Biosciences, Inc. (Exact name of Registrant as specified in its Charter) Delaware 47-3898435 (State or other jurisdictio ...
Arcus Biosciences (RCUS) Investor Presentation - Slideshow
2022-09-09 23:26
COMBINING TO CURE Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer. CORPORATE PRESENTATION September 2022 Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results to occur in the future contained in t ...
Arcus Biosciences(RCUS) - 2022 Q2 - Earnings Call Presentation
2022-08-12 01:54
COMBINING TO CURE Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer. 2Q22 CORPORATE PRESENTATION AUGUST 3, 2022 Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results to occur in the future contained ...
Arcus Biosciences(RCUS) - 2022 Q1 - Earnings Call Presentation
2022-05-18 05:51
COMBINING TO CURE Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer. 1Q22 Corporate Presentation May 9, 2022 Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results to occur in the future contained in ...
Arcus Biosciences(RCUS) - 2021 Q2 - Earnings Call Transcript
2021-08-08 04:37
Arcus Biosciences, Inc. (NYSE:RCUS) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Katherine Bock - VP, IR & Corporate Strategy Terry Rosen - Co-Founder, Chairman & CEO Robert Goeltz - Principal Financial & Accounting Officer & CFO Jennifer Jarrett - COO & Director Juan Jaen - Co-Founder, President & Director Kartik Krishnan - SVP, Clinical Development Conference Call Participants Alethia Young - Cantor Fitzgerald & Co. Peter Lawson - Barclays Bank Geoffrey Porges - SVB Leer ...